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The large specific granule of the human eosinophil contains a number of low 
molecular weight, highly basic proteins that have been purified to homogeneity, 
including the major basic protein (MBP) (1-3), 1 the eosinophil cationic protein 
(4,  5), and the eosinophil-derived  neurotoxin  (6,  7).  The comparative  physico- 
chemical and  immunochemical characteristics  of these  proteins  have  been  ex- 
amined in detail, and they clearly represent distinctive cationic  moieties of the 
granule. ~ MBP, the most abundant of the three proteins,  is a small polypeptide 
of 9,300 D (3) that has been localized by subcellular fractionation and immunoe- 
lectron  microscopy  to the electron-dense  crystalloid  core  of the guinea pig (8) 
and human (S. J.  Ackerman,  D.  A.  Loegering,  and  G. J.  Gleich,  unpublished 
observations) eosinophil granule. MBP has been regarded as a unique eosinophil 
protein and its release both in vitro and in vivo has been used as a specific marker 
for eosinophil localization, degranulation, and function (9-18). 
Using a sensitive double-antibody  immunofluorescent method (19),  MBP has 
been localized extracellularly in a number of tissues and organs whose dysfunc- 
tion in disease is generally associated with eosinophil infiltration (11, 20, 21).3 In 
these experiments, a small number of cells stained for MBP by immunofluores- 
cence that subsequently  could not be clearly  identified as eosinophils.  Because 
we recently demonstrated  that the Charcot-Leyden  crystal  (CLC) protein (lyso- 
phospholipase),  another eosinophil protein,  was also present in and crystallized 
from human basophils (22), we postulated that MBP might also be a constituent 
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of the blood basophii. We tested this hypothesis using highly purified suspensions 
of normal human basophils (23), a  sensitive radioimmunoassay (RIA) (15), and 
an immunofluorescence procedure (11,  19) for the detection of MBP. We now 
report that  normal  human  blood basophils  as well as basophils  from a  patient 
with basophil leukemia contain a protein that is immunochemically indistinguish- 
able from eosinophil MBP. 
Materials and Methods 
Preparation of Mononuclear Cells.  Basophil-containing mononuclear cell fractions were 
prepared  from  venous  blood  of normal  donors  by  Ficoll-Hypaque density  gradient 
centrifugation (24).  10-ml aliquots of blood anticoagulated with  buffered EDTA (pH 
7.35, 5 mM final concentration) were diluted with 30 ml of Hank's balanced salt solution 
(pH 7.35, calcium and magnesium free; Gibco Laboratories, Grand Island, NY) containing 
5 mM EDTA, 5.4 mM glucose, and 0.1% bovine serum albumin (Sigma Chemical Co., 
St. Louis, MO) (HEGA). Diluted blood was underlayered with 10 ml Histopaque (Sigma 
Chemical Co.) and centrifuged at 400 g for 30 min at room temperature. Cells at the 
plasma-Histopaque interface were removed, diluted 1:1 with ice-cold HEGA, and centri- 
fuged at 400 g at  4°C  for  10  rain.  Cell pellets were washed twice with  HEGA. This 
procedure yielded cell suspensions containing primarily lymphocytes and monocytes with 
0.5-2.0%  basophils as determined by alcian  blue staining  (25), and no eosinophils or 
neutrophils as determined by differential cell counts of Wright's-stained cytocentrifuge 
slides. 
Basophil Purification.  Highly enriched suspensions of blood basophils were prepared 
by flow microfluorometry using a fluorescence-activated  cell sorter (FACS IV; B-D FACS 
Systems, Becton, Dickinson & Co., Sunnyvale, CA) according to the method of Well et al. 
(23) as  previously described (22,  26).  Briefly, mononuclear cells  isolated as described 
above were labeled for 30 rain on ice with a  1:50 dilution of fluorescein isothiocyanate- 
conjugated IgG fraction sheep anti-human IgE (Cappei Laboratories, Cochranville, PA) 
in HEGA buffer. After three washings at 4°C in HEGA, the cells were sorted using the 
FACS IV. Bright fluorescent cells were sorted first at a rate of ~  10,000 cells/s without 
constraints and then re-sorted with contraints at a rate of ~  1,000 cells/s; ice-cold HEGA 
was used as the sheath and diluting fluid during sorting. The resultant cell preparations 
contained 87-97% basophiis, as determined by alcian blue staining (25) and by differential 
cell counts of cytocentrifuge slides fixed with absolute methanol and stained with Wright's 
stain, or fixed with Mota's fixative and stained with toluidine blue (27). FACS-purified 
basophil preparations did not contain any eosinophils or neutrophils and the contaminating 
cells consisted  of small  lymphocytes and  monocytes.  Basophils  in  the  FACS-purified 
preparations contained normal amounts of histamine (1.59 +  0. I  pg/basophil) as previ- 
ously reported (26). 
Eosinophil Purification.  Eosinophils were purified from venous blood of normal donors 
using the  method described by Vadas  et al.  (28).  Briefly, blood from healthy normal 
donors was collected in buffered EDTA, pH 7.35 (final concentration 5 raM).  Leukocytes 
and erythrocytes were separated by sedimentation of a mixture of 5 vol blood with 1 vol 
of 6% dextran T70 (Pharmacia Fine Chemicals, Piscataway, NJ) in Dulbecco's phosphate- 
buffered saline  (PBS)  (Gibco Laboratories) at  37°C  for 30-60  rain.  Eosinophils were 
purified further by discontinuous gradient centrifugation on a series of six metrizamide 
solutions (Nyegaard, Oslo, Norway) of 18, 20, 22, 23, 24, and 25% (wt/vol) as previously 
described (28).  The  discontinuous gradient  interfaces containing  85-95%  eosinophils 
were collected and washed three times by centrifugation at 400 g  with  HEGA buffer 
before use. Eosinophils were counted in a hemocytometer after staining with Randolph's 
phloxine-methylene blue (29). 
Eosinophil-rich leukocyte suspensions were obtained from two patients with the hyper- 
eosinophilic syndrome by cytapheresis on a semicontinuous flow cell processor (Haemo- 
netics Corp., Natwick, MA) as previously described (30). The anticoagulant used was 2% 
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cells in the supernatants were centrifuged at 400 g for 10 min, washed twice with RPMI 
1640 containing 10% fetal calf serum (Gibco Laboratories), resuspended in ice-cold RPMI 
1640 containing 40% fetal calf serum and 20% dimethylsulfoxide (Sigma Chemical Co.), 
aliquoted  at  1.0  x  107  eosinophiis  per  vial  into  Nunc  vials,  frozen  slowly to  -70°C 
(approximately -1 to -2°C/rain) and stored under liquid nitrogen (31). Eosinophils were 
recovered from liquid  nitrogen  storage according to the method of Holden et al. (31) 
with quick thawing of frozen aliquots at 37 °C and controlled dilution of the dimethylsulf- 
oxide-containing freezing  medium  to  maintain  maximum cell  viability. Cryopreserved 
eosinophils were washed twice by gentle centrifugation at 200 g  for  10  min in  HEGA 
before  use.  The  final  cell  preparations  from the  two  patients  contained  94  and  98% 
eosinophils. 
lmmunofluorescent Localization of MBP  and  CLC  Protein in  Basophils.  Cytocentrifuge 
slides of mononuclear cells  (see  Preparation  of Mononuclear  Cells)  or  FACS-purified 
preparations of basophils were stained for MBP and CLC protein by a double-antibody 
indirect  immunofluorescence  procedure  as  previously  described  (19,  22)  with  minor 
modifications. Briefly, cytocentrifuge slides were fixed for 5 min in absolute methanol, 
washed three times with PBS, and incubated overnight in  10% heat-inactivated normal 
goat  serum  in  PBS  at  4°C.  Slides  were  washed  three  times  in  PBS  and  placed  in  a 
humidified chamber.  To stain  for MBP,  slides were overlaid with  either a  protein  A- 
purified normal rabbit IgG (NRIgG) as negative control or an affinity chromatography- 
purified rabbit antibody to human MBP (ACP anti-MBP) used at equal IgG concentrations. 
The preparation of these reagents and the specificity for MBP localization in tissues and 
cells have been described in detail previously (20,  21).  To stain for CLC protein, slides 
were overlaid with a  1:40 dilution of either the preimmunization serum from the CLC- 
immunized rabbit as negative control or the postimmunization rabbit anti-CLC antiserum 
as previously described (22). After incubation overnight at 4°C, slides were washed three 
times  with  PBS,  stained  for  30  min  with  a  1%  solution  of chromotrope  2R  (16570; 
Harleco, Gibbstown, NJ) at room temperature, and washed again with PBS.  Slides were 
then overlaid with a  1:40 dilution of fluorescein-conjugated IgG fraction goat antirabbit 
IgG (13823;  Cappel  Laboratories), incubated for 30  min at  37°C,  washed three  times 
with  PBS,  mounted with a  10%  PBS/90%  glycerol solution containing p-phenylenedi- 
amine (P2396-2;  Aldrich Chemical Co.,  Milwaukee, WI) (32),  coverslipped, and sealed 
with clear nail polish. 
Slides were examined with a standard microscope (Carl Zeiss Inc., Oberkochen, Federal 
Republic of Germany) equipped with Zeiss IV FL vertical illumination for epifluorescence 
and a fluorescein filter system (487710; Carl Zeiss Inc.). Addition of p-phenylenediamine 
to the mounting medium significantly reduced fluorescent quenching (32), allowing for 
prolonged examination and multiple fluorescence photomicrographs of individual fields. 
Immunofiuorescence was photographed  using  Kodak Ektachrome 400  ASA  slide  film 
with 30-60 s exposure time. Background fluorescence resulting from the treatment of 
mononuclear cell fractions with fiuoresceinated sheep anti-human IgE for cell sorting on 
the FACS was minimal and did not interfere with the bright specific staining for either 
MBP or CLC protein. In some cases, fluorescent cells were photographed, the coverslips 
removed, the slides counterstained with Wright's stain, and the identical fields rephoto- 
graphed under normal transmitted light using ASA 64 Kodak Ektachrome slide film. 
Specificity Controls for lmmunofluorescence Staining  of MBP in Basophils.  Three types of 
specificity controls were used for immunofluorescence staining of MBP in basophils. First, 
immunofluorescence using preimmunization sera from individual rabbits was compared 
with immunofluorescence obtained using sera from the same rabbits after immunization 
with MBP. Second, immunofluorescence obtained with rabbit anti-MBP antisera absorbed 
with unrelated  Sepharose 4B-conjugated proteins, including histone and human serum 
albumin  (HSA),  or  unconjugated  Sepharose,  was  compared  with  that  obtained  using 
antisera absorbed with the homologous solid-phase antigen,  MBP-Sepharose. Sepharose 
4B was activated by cyanogen bromide and 2 mg of histone, HSA, or MBP was coupled 
to  1 ml of Sepharose 4B.  Uncoupled sites were blocked with 0.1  M lysine monohydro- 
chloride. Protein-Sepharose conjugates were washed with 0.05 M glycine-HC1 buffer, pH ACKERMAN  ET  AL.  949 
3.0, and used to absorb sera (1  ml conjugate to 2 ml of a  1:10 serum dilution). Third, 
immunofluorescent staining of basophils by ACP anti-MBP was compared with staining 
obtained using a protein A-purified NRIgG at equivalent concentrations of rabbit IgG 
(see Immunofluorescent Localization of MBP and CLC Protein in Basophils). 
Preparation of Cell Extracts.  Basophil-,  eosinophii-,  and  mononuclear  cell-enriched 
suspensions were centrifuged at 400 g and the cell pellets resuspended in small volumes 
(0.25-1.0 ml) of 0.1  M phosphate buffer (Na,HPO4-KH2PO4, pH 7.4) containing 0.1% 
protamine sulfate, 0.5% newborn calf serum, and 0.1% sodium azide (PPF buffer) with 
1.0%  Triton  X-100  (Sigma  Chemical  Co.).  These  suspensions  were  subjected  to  I0 
successive freeze-thaw cycles using dry ice-acetone and a 37°C water bath, with vortexing 
between each cycle. Extracts were centrifuged at 12,000 g for 10 rain. The resulting clear 
supernatants were stored on ice, and MBP levels were measured immediately by RIA. 
Measurement of  MBP Levels in Cell Extracts by Radioimmunoassay.  MBP concentrations in 
the cell extracts were measured by a double-antibody radioimmunoassay (RIA) as previ- 
ously described (15). Measurement of maximal MBP concentrations requires reduction 
and alkylation of samples before RIA (15,  33).  Therefore, aliquots of each cell extract 
were diluted  1:1  with a buffer consisting of 0.12 M  NaCI, 0.01  M EDTA, and 0.33 M 
Tris hydroxymethyi aminomethane (TRIZMA base; Sigma Chemical Co.), pH 8.0. A 0.1 
M solution of dithiothreitol (Sigma Chemical Co.) was added to achieve a final concentra- 
tion of 0.0075 M, and the sample was incubated at room temperature for 60 rain. Next, 
a  0.2  M  solution of iodoacetamide (Sigma Chemical Co.) was added to achieve a final 
concentration of 0.015 M and the incubation continued for an additional 20 min at room 
temperature. Samples were diluted further in PPF buffer as required for RIA. The RIA 
results were expressed as a percentage of the maximum ~3~I-MBP bound, and data were 
analyzed by  unweighted logit-log transformation  using  a  computer  (9845B;  Hewlett- 
Packard Co., Palo Alto, CA) with RIA program No. 09845-14254 and regression analysis 
methods program No. 09845-15014. 
In one experiment (see Fig. 4), MBP levels in basophii extracts were measured using a 
two-site immunoradiometric assay  (TSIRA) (34) as described in  detail elsewhere (35). 
Briefly, protein A-purified rabbit IgG anti-MBP antibody was bound to plastic wells of a 
Microelisa  96-well  flexible plastic  plate  (Dynatech  Laboratories,  Inc.,  Freehold,  NJ), 
incubated with dilutions of reduced and aikylated basophil extract or MBP standard, and, 
after extensive washing, the resulting bound MBP was detected by adding radiolabeled 
~5I-ACP anti-MBP. After further washing, the wells were cut out and counted as described 
above. 
Preparation of Human Basophil Leukemia Cells.  Basophii leukemia cells were obtained 
from a Mayo Clinic patient with basophil leukemia (T. M. Habermann, S. J. Ackerman, 
G.J. Gleich, and P. R. Greipp, manuscript in preparation). Cells for immunofluorescence 
and cell extraction were obtained from heparinized blood. For immunofluorescence, 10 
ml heparinized blood was diluted with 30 ml of HEGA buffer and underlayered with 10 
ml of Histopaque. After centrifugation at 400 g for 30 min at room temperature, the cells 
at the plasma-Histopaque interface were removed and washed three times in HEGA with 
centrifugation at 400 g before preparation of cytocentrifuge slides. The final cell suspen- 
sions contained 80% basophils as determined by alcian blue staining (26) and differential 
counts of toluidine blue-stained cytocentrifuge slides  (27).  The remainder of the cells 
were primarily mononuclear (lymphocytes and monocytes) with no eosinophiis. Cells for 
extraction and MBP RIA were prepared in the identical fashion. Cell pellets containing 
1.3 ×  107 basophils were resuspended in 0.5 ml of PPF buffer with 1% Triton X-100 and 
soluble extracts prepared as described above. 
Results 
Detection of MBP in  Basophils  by Immunofluorescence.  To  determine  whether 
basophils  contained  immunoreactive  MBP,  we  stained  cytocentrifuge slides  of 
basophil-containing mononuclear cell preparations and FACS-purified prepara- 
tions  of basophils  for  MBP  by  immunofluorescence.  When  mononuclear  cell 950  EOSINOPHIL  GRANULE  MAJOR  BASIC  PROTEIN  IN  BASOPHILS 
preparations were stained with ACP anti-MBP antibody, a  small percentage of 
cells fluoresced brightly with a  speckled or granular staining pattern  (Fig.  1 a 
and c). The mononuclear cell preparation contained primarily lymphocytes and 
monocytes, and  was  slightly  enriched  for  basophils  ('--2%)  as  determined  by 
alcian  blue  staining.  The  mononuclear cell  preparations  did  not  contain  any 
eosinophils or neutrophils as determined by differential cell counts of duplicate 
Wright's  stained  slides.  When  slides stained  by immunofluorescence for  MBP 
were  counterstained  with  Wright's  stain  and  the  identical  microscopic  fields 
examined, the morphology of the cells showing granular fluorescence was not 
distinctive  (Fig.  1  b  and  d).  Although  the  cells  possessed  polymorphic  nuclei 
characteristic of basophils, their granular morphology was not preserved by this 
procedure. 
To  determine  whether  an  enrichment  for  surface  IgE-positive  cells,  i.e., 
basophiis, would also enrich for cells staining positively by immunofluorescence 
for MBP, immunofluorescent staining was performed on cytocentrifuge slides of 
FACS-purified basophils.  Slides were stained by immunofluorescence for both 
MBP and CLC protein, and by standard histochemical stains for the identification 
of  basophils  by  their  characteristic  granule  metachromasia  (Fig.  2).  FACS- 
purified, surface IgE-positive cells stained with toluidine blue showed the typical 
FIGURE  1.  Immunofluorescentstainingofbasophil-containingmononuclearcellpreparations 
for  MBP.  (a  and  c)  Fluorescence photomicrographs  (×  400,  ×  1,000,  respectively)  of a 
cytocentrifuge slide of a mononuclear cell preparation containing  basophils, lymphocytes, and 
monocytes, but no eosinophi]s.  Note  the  bright  fluorescent cells  with distinctive granular 
staining. (b and d) Identical fields to a and c, counterstained with Wright's stain, showing the 
polymorphonuclear appearance of the  cells  that  stained by immunofluorescence (arrows), 
presumably basophils, the granular morphology of which has been lost before counterstaining 
with Wright's stain. Note that the mononuclear cells do not stain for MBP by immunofluores- 
cence. ACKERMAN  ET  AL.  951 
FIGURE 2.  Immunofluorescent staining of FACS-purified basophils for MBP and CLC pro- 
tein. (a) FACS-purified basophils (>95% basophils) stained with toluidine blue (X 400, inset x 
1,000).  Note the typical polymorphic nuclei and granularity of the cytoplasm typical of blood 
basophils. (b) Cells stained by immunofluorescence using NRIgG as negative control (x 400). 
Note the absence of any fluorescent staining. (c and d) Cells stained by immunofluorescence 
for MBP  using ACP anti-MBP (X  400,  x  1,000,  respectively). Note the bright distinctive 
granular fluorescence (arrow). (e and./) Cells stained by immunofluorescence for CLC protein 
(x 400, x  1,000,  respectively). In comparison with the granular fluorescence of cells stained 
for MBP (c and d), staining for CLC protein produces a much brighter but diffuse cytoplasmic 
and perinuclear staining (e and  f). 
granule  metachromasia  of blood  basophils  (Fig.  2  a).  Slides  stained  with  ACP 
anti-MBP (Fig.  2 c and d) showed a bright granular staining pattern that was not 
observed  when  these  cells  were  stained  with  NRIgG  as  negative  control  for 
immunofluorescence  (Fig.  2  b). For comparative  purposes,  we also stained these 
cells  for  CLC  protein,  another  eosinophil  protein  recently  localized  to  human 
basophils (22).  The bright diffuse  cytoplasmic  and perinuclear  staining pattern 
for CLC protein  (Fig.  2  e and f)  differed  markedly  from  that of the distinctive 
granular pattern observed  for MBP (Fig.  2 c and d). 952  EOSINOPHIL  GRANULE  MAJOR  BASIC  PROTEIN  IN  BASOPHILS 
As shown in Table I, >95 % of the surface IgE-positive cell populations in these 
experiments  were  basophiis,  as  assessed  by  staining  with  alcian  blue  or  by 
differential cell counts  performed  on  cytocentrifuge  slides stained  with  either 
toluidine blue or Wright's stain.  Likewise, differential cell counts performed  on 
duplicate  slides  stained  for  MBP  and  CLC  protein  by  immunofluorescence 
showed that >95%  of the cells in these preparations also fluoresced brightly with 
the granular fluorescent pattern for MBP or diffuse cytoplasmic and perinuclear 
pattern  for CLC protein.  These  results show clearly that  FACS enrichment  for 
surface  IgE-positive cells,  primarily  basophils,  also  enriched  for  cells  staining 
positively for MBP by immunofluorescence  (Table I). 
TABLE  I 
Analyses of Purified Basophil Preparations by Histochemical Staining 
and by Immunofluorescence for MBP and CLC Protein * 
Percent basophils 
Staining method 
Percent positive cells 
Immunofluorescence 
for: 
Alcian  Toluidine  Wright's  CLC  MBPI 
blue  *  blue  s  stain  I  Protein  s 
Experiment 1  95.2  97.6  97.7  96.1  98.5 
Experiment 2  97.4  95.2  95.2  96.4  97.2 
* Differential cell counts of FACS-purified basophils by alcian blue staining of cells in 
suspension or staining of cytocentrifuge slides with toluidine blue, Wright's stain, or 
by immunofluorescence for CLC protein and MBP. There were no eosinophils in 
these preparations and the few contaminating cells consisted of small lymphocytes 
and monocytes. 
*  Hemocytometer counts. 
0  Differential counts on 1,000 cells. 
TABLE  II 
Spec~city of lmmunofluorescent  Staining for MBP in Human Basophils* 
Reagent tested  Absorption  ~: 
Basophil 
fluorescence  0 
Rabbit  Rabbit 
2  4 
Rabbit anti-MBP serum  None  +  + 
Unconjugated Sepharose  +  + 
Histone-Sepharose  +  + 
HSA-Sepharose  +  + 
MBP-Sepharose  -  - 
Preimmunization serum  None  NT  - 
ACP rabbit anti-MBP  None  NT  + 
NRIgG  !  None  NT  - 
* The specificity of immunofluorescence for MBP in basophils was tested by staining 
cytocentrifuge slides of basophil-containing mononuclear cell preparations (primarily 
mononuclear cells with 1-2% basophils and no eosinophils). 
* Rabbit  anti-MBP  sera  from  two  rabbits  were  absorbed  with  various solid-phase 
immunosorbents before use as a first-stage reagent for immunofluorescence. 
s +, bright fluorescent staining; -, absence of fluorescent staining; NT, not tested. 
I Protein A-purified NRIgG from a normal rabbit serum pool. ACKERMAN  ET  AL.  953 
The  specificity of immunofluorescence staining for  MBP  in  basophils was 
assessed in three different ways (Table II). First, two different rabbit antisera to 
MBP were absorbed with various protein-Sepharose conjugates, and the absorbed 
antisera  were  used  in  the  first  stage  of the  immunofluorescence procedure. 
Absorption with the unrelated cationic protein histone coupled to Sepharose, 
HSA-Sepharose, or unconjugated Sepharose did not abrogate the bright granular 
staining of the basophils.  In contrast, absorption with the  homologous solid- 
phase  antigen,  MBP-Sepharose,  completely eliminated  fluorescence  staining. 
Second, immunofluorescent staining was not produced using the preimmuniza- 
tion serum from the  MBP-immunized rabbits.  Third,  ACP anti-MBP stained 
basophils brightly whereas a protein A-purified NRIgG (negative control), tested 
at the same IgG concentration, did not stain basophils. 
Measurement of MBP in Freeze-Thaw Detergent Extracts  of FACS-purified  Basophils 
by RIA.  To test whether basophiis and eosinophils contained similar quantities 
of MBP, we measured MBP concentrations in the supernatants of freeze-thaw 
detergent extracts of various cell suspensions enriched for basophils by FACS, 
for eosinophils by discontinuous gradient centrifugation of normal peripheral 
leukocytes and  by  e0sinapheresis of patients with  the  hypereosinophilic syn- 
drome, and for mononuclear cells (basophil enriched, eosinophil depleted) by 
centrifugation over Histopaque (Table III). MBP was detected in all cell extracts 
that contained eosinophils, as well as in extracts prepared from FACS-purified 
basophils (92  and  89%  purity in  experiments 2  and 4,  respectively, with no 
contaminating eosinophils) and  from  mononuclear cell  suspensions that  con- 
tained 0.54  and  1.9%  basophils in experiments 2  and  4,  respectively.  When 
extracts were compared on the basis of MBP content per 106 cells, the basophil 
and eosinophil extracts contained more MBP than did the unseparated mono- 
nuclear cell  extracts (Table  III).  In addition, when the MBP content per  10  6 
basophils or  10  6 eosinophils was calculated, eosinophils contained considerably 
more MBP than did basophils. A summary of the comparative MBP content of 
TABLE  III 
MBP in Freeze-Thaw Detergent Extracts of Human Leukocyte Preparations* 
Total cells ex-  ng MBP/  ng MBP/10  s  ng MBP/  ng MBP/10  s 
Percent  Percent  tracted  106 baso-  eosinophiis 
Cell extract analyzed  basopbil  eosinophil  (× 10-s~  extract  ceils  phils 
Experiment 2 
Basophi!  92  --  5.4  36  67  72  -- 
Mononuclear  1.9  --  200.0  37  2  97  -- 
Eosinophil  (patient  1)  --  98  100.0  11,246  1,125  --  I, 148 
(patient 2)  --  94  1O0.0  8,923  892  --  949 
Experiment 4 
Basophil  89. l  --  1.5  6  40  43  -- 
Mononudear  0.54  --  200.0  9  <1  86  -- 
Eosinophil  (patient  1)  --  98  100.0  8,253  825  --  842 
(patient 2)  --  94  100.0  8,008  801  --  852 
Eosinophil  (normal donor  1)  --  95.5  65.0  17,756  2,732  --  2,860 
(normal donor 2)  --  84.7  15.0  9,447  6,298  --  7,440 
* MBP levels in soluble extracts of purified basophils, mononuclear cells, and eosinophils were determined  by RIA. Cell counts performed as 
described in Materials and Methods. 
* Cells in experiment  2  from  the basophil,  mononuclear,  and eosinophil patients  1 and  2  preparations  were extracted  in volumes of 0.256, 
0.54,  1.0, and  1.01 ml; and cells in experiment 4 from the basopbil, mononuclear, eosinophil patients 1 and 2, and eosinophil normal donors 
I  and 2  preparations were extracted in volumes of 0.225, 0.255, 0.5l, 0.53, 1.01. and  ].02 ml PPF with Triton X-I00, respectively. 954  EOSINOPHIL  GRANULE MAJOR BASIC PROTEIN  IN  BASOPH1LS 
normal  basophils  from  four  different  donors,  normal  eosinophils  from  two 
different donors, and eosinophils from two patients with the hypereosinophilic 
syndrome, for four separate experiments, is shown in Table IV. Normal basophils 
averaged  140  +  128  ng  MBP/106  cells  (9,  +  1  SD,  n  =  7),  whereas  purified 
eosinophils from patients with the hypereosinophilic syndrome and from normal 
donors averaged  824  4-  173  (n  =  8) and 4,979  4-  2,383  (n  =  4) ng MBP/106 
cells, respectively. Therefore, normal basophils contained, on the average,  17% 
of the MBP detectable in eosinophils from patients with the hypereosinophilic 
syndrome and 2.8% of the MBP detectable in eosinophils from normal healthy 
donors. 
The  RIA measures MBP concentrations via the inhibition of the binding of 
radiolabeled  IalI-MBP  to  specific  antibody.  Fig.  3  a  and  b  shows  the  RIA 
inhibition curves obtained when increasing quantities of reduced and alkylated 
extracts  of  the  various  purified  cell  suspensions  were  reacted  with  specific 
antibody to MBP and  1 ng 13q-MBP.  The slopes of the inhibition curves were 
very similar within each experiment, and basophil extracts inhibited the binding 
of radiolabeled  MBP as  well as  the  MBP  primary standard  or  the  eosinophil 
extracts. Fig. 3 c and d shows the regression analysis for a logit-log transformation 
of these data. Statistical comparison of the regression lines by analysis of covari- 
ance showed no significant differences in their slopes. The finding that the slopes 
of the inhibition curves for the basophil extracts were not significantly different 
from those of the  MBP primary standard  or  the other  cell extracts prepared 
from eosinophils indicates that basophils contain a protein that is immunochem- 
ically indistinguishable from that of the eosinophil granule MBP. 
In  addition  to analyzing the  basophil  extracts  by double-antibody  RIA,  we 
TABLE  IV 
Comparative MBP Content of Basophils and Eosinophils as Determined by 
RIA of Freeze-Thaw Detergent Extracts of Various Leukocyte Preparations 
Cell extract analyzed  Expt. 1  Expt.  2  Expt.  3  Expt.  4 
ng MBP/106 basophils* 
Basophil*  406  72  ND  43 
Mononuclear  ~  204  97  72  86 
ng MBP/106 eosinophils 
Eosinophil  I  (patient 1)  734  1,148  559  842 
(patient 2)  766  949  745  852 
Eosinophil  ~ (normal donor 1)  ND  ND  3,015  2,860 
(normal donor 2)  ND  ND  6,600  7,440 
* MBP levels in  basophils obtained from a different normal donor  for each 
experiment. ND, not done. 
* Purity of FACS-purified  basophil preparations for expts. 1, 2, and 4 was 87.3, 
92.0, and 89.1%, respectively. 
Mononuclear cell preparations for expts. 1-4 contained 0.57, 1.9, 1.63, and 
0.54% basophils, respectively,  and no eosinophils. 
! Eosinophil preparations from hypereosinophilic syndrome patients 1 and 2 
contained 98 and 94% eosinophils, respectively. 
Eosinophil preparations from normal donors 1 and 2 contained 95.5 and 84.7% 
eosinophils, respectively. ACKERMAN ET  AL.  955 
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Inhibition of the binding of ~s~I-MBP to specific antibody by MBP primary 
standard and  freeze-thaw detergent  extracts of purified human  basophils, eosinophils, and 
mixed mononuclear leukocytes containing a small percentage of basophils. (a) Inhibition curves 
produced  in  experiment  2  when  increasing quantities of MBP  standard  ((3) or increasing 
amounts of freeze-thaw extracts of purified human  hasophils (0), unseparated mononuclear 
leukocytes containing 1.9% basophils (A), or eosinophils from hypereosinophilic patient 1 (&) 
or 2  (l'-I) were analyzed in the double-antibody RIA. (b) Regression lines for the logit-log- 
transformed data in a. The coefficient of determination (r  ~) for the MBP standard inhibition 
regression line was 0.992 and for cell extracts, an average of 0.995 +  0.004. Comparison of 
these logit-log regression lines by analysis of covariance showed that the null hypothesis of 
common slope could not be rejected (F4.t4 =  2.26; not significant). 
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FIGURE 4.  Comparative  binding  curves  for  MBP  standard  and  a  freeze-thaw  detergent 
extract of purified human basophils (93.2%) in the TSIRA. (a) Binding curves produced when 
increasing amounts of either MBP standard (O) Or basophil extract (0) were analyzed by the 
TSIRA.  (b) Regression analysis for the  logit-log-transformed data in a. The coefficient of 
determination  (r  2) for  the  MBP  standard  was  0.997  and  for  the  basophil extract,  0.960. 
Comparison of these regression lines by analysis of covariance showed that a null hypothesis 
of common slope could not be rejected (F~.5 =  0.91; not significant). 
performed a TSIRA involving the direct binding of MBP to specific antibody in 
the form of an  antibody-antigen-antibody  sandwich.  The  binding  curves com- 
paring a titration of MBP primary standard with that of a reduced and alkylated 
basophii extract in the TSIRA are shown in Fig. 4 a. As with the double-antibody 
RIA, a comparison of the regression lines for a logit-log transformation of these 
data did not show any significant differences in the slopes of their binding curves. 
Detection of MBP in Basophil Leukemia Cells.  Leukemic cells obtained from the 
peripheral  blood of a  patient  with  basophil  leukemia  were analyzed  for  their 
MBP content by immunofluorescence and by RIA of freeze-thaw detergent cell 956  EOSINOPHIL  GRANULE  MAJOR  BASIC  PROTEIN  IN  BASOPHILS 
extracts. These preparations contained 80% basophils with typical granule met- 
achromasia. Immunofluorescence staining of cytocentrifuge slides for MBP and 
CLC protein revealed the identical staining patterns observed for each of these 
proteins in normal basophils, with granular staining for MBP and brighter but 
more  diffuse  cytoplasmic  staining  for  CLC  protein  (Fig.  5).  In  general,  the 
staining of basophil leukemia cells for MBP was more variable and less intense 
(Fig.  5  a)  than  that  of normal  basophils  (Fig.  2  c and  d);  by comparison,  the 
intensity of staining  for CLC protein was roughly equivalent for both normal 
(Fig.  2  e  and J)  and  leukemic cells  (Fig.  5  c).  As  with  normal  basophiis,  the 
leukemic cells did not stain by immunofluorescence when NRIgG or a  preim- 
munization serum was substituted for specific antibody (Fig. 5 b and d). 
Analysis of soluble extracts of the basophil leukemia cells by RIA revealed a 
significantly lower content of MBP: 9 and  18 ng MBP per  106 basophils in two 
experiments  as  compared  with  an  average  of  140  ng  MBP  per  106  normal 
basophils (see Table IV). 
FIGURE 5.  Comparative staining of basophil  leukemia cells for MBP and  CLC protein  by 
immunofluorescence, (a) Immunofluorescent staining of cells for MBP using ACP anti-MBP. 
(b) Negative control for a stained by immunofluorescence using N RIgG. (c) Immunofluorescent 
staining of cells for CLC protein.  (d)  Negative control for c stained by immunofluorescence 
using the preimmunization normal rabbit serum. Note that the basophil leukemia ceils (~ 80% 
basophils)  stained  with  the  same  granular  fluorescence  for  MBP  and  with  more  intense 
cytoplasmic and perinuclear fluorescence for CLC protein.  Comparison of the immunofluo- 
rescence staining for MBP in a  with that in Figs.  1 and  2 shows that basophil leukemia cells 
stained  less  brightly  for  MBP  than  did  normal  basophils,  consistent  with  their  lower  MBP 
content as determined by RIA. ACKERMAN ET  AL.  957 
Discussion 
MBP,  the sole cationic constituent  of the distinctive crystalloid core of the 
eosinophil's large specific granule (8) (S. J. Ackerman, D. A. Loegering, and G. 
J.  Gleich,  unpublished  observations),  is  currently  considered  unique  to  the 
eosinophil.  As  such,  it  has  been  used  as  a  marker  for  studies  of eosinophil 
function  in  health  and  disease  (13,  36)  through  its  cellular and  extracellular 
localization in tissues (11,  19-21), s its presence in body fluids such as serum (14, 
15)  or  sputum  (10),  and  in  vitro as  a  marker  of eosinophil  degranulation  in 
studies of the eosinophil's function as an effector cell for parasite killing (9,  12). 
Using an  immunofluorescence procedure  (19),  MBP  has  been  localized in  a 
number of tissues and organs whose dysfunction in certain diseases is associated 
with either peripheral blood eosinophilia and/or obvious eosinophil infiltration 
(11, 20, 21). 3 During the course of these investigations, a very small number of 
cells have been observed that stained for MBP by immunofluorescence, but upon 
counterstaining could not be clearly identified as eosinophils.  In certain cases 
these cells may have been partially degranulated eosinophils; in others, MBP may 
have been ingested by other cells such as alveolar macrophages (11). Examination 
of peripheral blood smears clearly showed cells staining for MBP that were not 
eosinophilic.  Because  we  had  already  demonstrated  that  another  prominent 
eosinophil protein, the Charcot-Leyden crystal protein (lysophospholipase), was 
also a blood basophil constituent (22), we tested the hypothesis that MBP might 
be present in basophils. 
For  this  purpose,  we  stained  slides  of eosinophil-free,  basophil-containing 
mononuclear cell preparations (1-2% basophils) (Fig. 1), highly purified basophil 
preparations (>95%) (Fig. 2), and cells from a basophil leukemia patient (>80% 
basophils) (Fig. 5) for MBP by a sensitive and specific (Table II) immunofluores- 
cence  procedure  (11,  19-21).  In  all  cases,  ceils  with  the  distinctive  nuclear 
morphology and granule metachromasia typical of basophilic leukocytes stained 
brightly for MBP, with a granular staining pattern consistent with localization in 
the histamine-, heparin-containing granule (Figs.  1, 2, and 5).  The fluorescent 
localization  of MBP  in  these  cells  was  distinctly  different  from  the  staining 
pattern observed for CLC protein (22), which was considerably brighter, with a 
diffuse cytoplasmic and perinuclear localization (Figs. 2 and 5). Basophils possess 
considerable quantities  of cell surface  IgE, and we enriched for  surface  IgE- 
positive cells using the FACS, thereby obtaining cell suspensions containing up 
to 97% basophils, without any contaminating eosinophils (Tables I, III, and IV). 
When  these  cell  preparations  were  stained  by  three  different  histochemicai 
procedures, >95% of the cells were basophils and >95% also fluoresced brightly 
when stained for either MBP or CLC protein  (Table I, Fig. 2).  Likewise, cells 
obtained  with  considerably  fewer  in  vitro  manipulations  from  a  patient  with 
basophil leukemia contained MBP and CLC protein when stained by immunoflu- 
orescence (Fig. 5); when stained with toluidine blue, >80% of these cells showed 
the metachromatic granular staining typical of blood basophils in various s~ages 
of maturity.  Finally,  we  demonstrated  the  presence  of MBP  in  basophils  by 
preparing  freeze-thaw  detergent  extracts  of  highly  enriched  suspensions  of 
basophils and basophil-containing mononuclear cells from four different normal 
donors,  and  eosinophils  from  two  normal  donors  and  two  patients  with  the 958  EOSINOPHIL  GRANULE  MAJOR  BASIC  PROTEIN  IN  BASOPHILS 
hypereosinophilic syndrome. We compared the ability of these soluble extracts 
to inhibit the binding of radiolabeled MBP to specific antibody in an RIA or to 
bind antibody to MBP in a  TSIRA.  The results of these experiments (Figs.  3 
and 4) indicate that basophils contain a protein that is immunochemically indis- 
tinguishable from either purified MBP or the MBP present in soluble extracts of 
normal eosinophils or eosinophils from patients with the hypereosinophilic syn- 
drome. We calculated the MBP content of normal basophils and they contained 
considerably less MBP than did normal eosinophils or eosinophils from patients 
with the hypereosinophilic syndrome (2.8 and 17%, respectively) (Tables III and 
IV).  In addition, basophils from the patient with basophil leukemia contained 
even less M BP (9-18 ng/106 cells) than did normal basophils (140 ng/106 cells). 
Based  upon these results,  MBP can  no  longer be considered unique to the 
eosinophil, and the basophil's potential contribution to observed serum or other 
body fluid levels or tissue localization of MBP in health or disease must be taken 
into account. Although the MBP in the basophil appears by immunofluorescence 
to be  localized to the histamine-, heparin-containing granule,  this localization 
needs  to  be  confirmed by  appropriate  studies  using subcellular  fractionation 
and/or immunoelectron microscopy. The role of MBP in basophil function is a 
matter of speculation. Exogenously added native or reduced and alkylated MBP 
was recently shown to stimulate basophil histamine secretion in vitro by an IgE- 
independent, noncytolytic mechanism (24) similar to that induced by polycations 
such as poly-L-arginine (37).  However,  the mechanism by which MBP induces 
basophil histamine secretion and the possibility that the secretion of the endog- 
enous MBP from the basophil granule has a similar histamine-releasing function 
remain to be determined. 
The current finding that two proteins, MBP and CLC, heretofore considered 
unique to the eosinophil, are  also constituents of the blood basophil indicates 
biochemical  similarities  between  these  cells  and  suggests  the  existence  of a 
common hemopoietic progenitor for basophils and eosinophils. In fact, results 
of recent studies of eosinophil and basophil colony growth in vitro (38,  39) are 
consistent  with  the  hypothesis  that  these  cells  share  a  common  committed 
hemopoietic progenitor cell in bone marrow and peripheral blood. If this were 
true,  one  might  also  expect  to  find  other  common eosinophil  and  basophil 
proteins, such as the eosinophil cationic protein (4,  5),  the eosinophil-derived 
neurotoxin (6), or the eosinophil peroxidase (40). Indeed, previous studies have 
shown that basophils contain peroxidase activity (41, 42). 
Summary 
In experiments using an immunofluorescent method to localize human eosin- 
ophil granule major basic protein (MBP) in cells and tissues, a  small number of 
cells stained for MBP that subsequently could not be identified as eosinophils. 
Because  the  Charcot-Leyden  crystal  protein,  another  eosinophil protein,  was 
recently identified in basophils, we tested whether MBP might also be a constit- 
uent of blood basophils.  Highly purified,  eosinophil-free basophil  suspensions 
were prepared using the fluorescence-activated cell sorter (FACS) to sort baso- 
phil-containing  mononuclear  cell  preparations  stained  with  fluorescein-conju- 
gated sheep IgG anti-human IgE antibody. Using these FACS-purified basophils, ACKERMAN ET  AL.  959 
we found that: (a) enrichment for surface IgE-positive cells (>95% basophils) by 
FACS also enriched for cells staining for MBP by immunofluorescence; (b) MBP 
appeared  to  be  localized  in  the  histamine-,  heparin-containing  granules;  (c) 
significant  quantities  of MBP were measurable by radioimmunoassay  (RIA) in 
freeze-thaw detergent extracts of purified basophils; and (d) RIA dose-response 
curves for extracts of purified eosinophils and basophils had identical slopes. The 
MBP content of basophils from normal  individuals averaged  140 ng/106 cells, 
whereas purified eosinophils from normal  donors and patients with the hyper- 
eosinophilic syndrome averaged 4,979 and 824 ng/106 cells, respectively. MBP 
was also  detected  by immunofluorescence  and  RIA  in  cells  obtained  from  a 
patient with basophil leukemia, although the MBP content for basophil leukemia 
cells  was  lower  than  that  for  normal  basophils.  We  conclude  that  basophils 
contain  a  protein  that  is  immunochemically  indistinguishable  from  eosinophil 
granule MBP. 
We wish to thank Jim Tarara for excellent technical assistance in operating the FACS for 
basophil purification,  D. Maddox for performing the TSIRA, L. Thomas for the histamine 
determinations, and L. Callister for preparation of the manuscript. 
Received  for publication 26 May 1983. 
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